Story
Jefferies Upgrades Dormakaba to 'Buy' on Margin Expansion and US Growth Prospects

Summary
Jefferies raised its rating on Swiss security group Dormakaba to 'Buy' from 'Hold', setting a new CHF 82 price target that implies 34% upside, citing a valuation discount and the potential for improved profitability.
Jefferies has upgraded Swiss access-solutions maker Dormakaba Holding AG (SIX:DOKA) to "Buy" from "Hold," citing a compelling valuation and significant scope for margin expansion. The investment bank raised its price target to CHF 82 from CHF 70, which implies a potential 34% upside from the stock's Sept. 25 closing price of CHF 61.30.
Margin and Valuation Catalysts
The upgrade is anchored in Jefferies' expectation that Dormakaba's adjusted EBITDA margins will climb to approximately 18% by fiscal 2028/29, which is 80 basis points above the market consensus. This forecast is supported by the company's recent performance, including a record adjusted EBITDA margin of 16.1% in fiscal 2025/26, driven by a successful restructuring program that delivered CHF 235 million in savings, well above its CHF 170 million target.
According to the brokerage, Dormakaba's shares are trading at a significant discount. The stock is valued at about 14 times its estimated 2026 enterprise value to adjusted EBITA (EV/EBITA), which is approximately 20% below its long-term average multiple of 17.8 times.
Strategic Drivers and Outlook
Growth in North America, which accounts for about 30% of the company's exposure, remains a key driver for the positive outlook. Jefferies forecasts organic growth in the region to reach 8% in fiscal 2027/28. The bank's estimates project U.S. and Canada sales reaching CHF 852 million by fiscal 2028/29, excluding any potential acquisitions.
AdA proposed simplification of the company's ownership structure is another potential positive catalyst. The plan involves the Mankel family exchanging its 47.5% stake in the operating company for newly issued shares in the listed entity. Jefferies estimates this could create about CHF 2 billion in capital contribution reserves, which could potentially be distributed to shareholders without incurring Swiss withholding tax.
Key Data and Risks
Investors will be watching for potential updates at the company's upcoming Capital Markets Day on Nov. 18. Key financial details from the Jefferies note include:
- Bull-case Price Target: CHF 104
- Bear-case Price Target: CHF 45
- FY 2025/26 Revenue: CHF 2.79 billion, with 3.0% organic growth.
- Ownership Vote: Shareholders will vote on the new structure at the annual general meeting on Oct. 20.
The primary risk to the investment thesis is execution, particularly if the U.S. growth strategy takes longer than anticipated to deliver results. Jefferies cautioned that while the U.S. business recovered in the second half of fiscal 2025/26, one strong half-year does not definitively establish a long-term trend.
Read next
More on Stocks
SpaceX Starship Achieves Orbit, Deploys Satellites in Milestone 14th Flight
SpaceX's next-generation Starship rocket successfully reached orbit for the first time and completed its first operational satellite deployment, marking a major step toward routine service for the heavy-lift vehicle.

Berkshire Hathaway Buys $136M in Lennar Stock as Tech Executives Unload Shares
Warren Buffett's Berkshire Hathaway disclosed a major purchase of Lennar Corp. shares, while executives at CrowdStrike, Robinhood, and other tech firms sold millions in stock, many through pre-arranged trading plans.

Gold Fields Stock Sinks After Northern Star Rejects $27.1 Billion Merger Bid
Gold Fields shares fell sharply after its unsolicited A$38.7 billion takeover proposal was unanimously rejected by the board of Australian miner Northern Star Resources, with investors citing concerns over the deal's dilutive structure.

MediciNova Shares Tumble After NAFLD Drug Misses Primary Trial Endpoints
Shares of MediciNova Inc. fell sharply after the company's Phase 2 drug candidate, tipelukast, failed to meet its main goals in a study for non-alcoholic fatty liver disease, disappointing investors.